GlassScriptPhysician profile
Francesca Cerimele
NPI 1770591950
$2,928.73
in general payments reported to CMS, 2019-2025
33 companies · $67.86 in 2025
The $67.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2020: $807 · 2021: $253 · 2022: $166 · 2023: $244 · 2024: $170 · 2025: $67.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $482.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.15 | 2019-2025 | Qulipta, Vraylar, Creon |
| Glaxosmithkline, LLC. | $332.81 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Amgen INC. | $291.14 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $286.89 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $228.40 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.47 | 2019-2021 | |
| Amarin Pharma, INC. | $130.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $94.86 | 2019-2020 | |
| Novo Nordisk INC | $84.42 | 2019-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $77.10 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $64.62 | 2019-2020 | |
| Allergan, INC. | $62.38 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $47.48 | 2020 | |
| Orexo US, INC. | $43.15 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.73 | 2019-2020 | |
| Daiichi Sankyo INC. | $39.99 | 2019 | |
| Grifols USA, LLC | $31.44 | 2019 | |
| Medtronic, INC. | $30.37 | 2022 | |
| Genentech USA, INC. | $29.85 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.76 | 2019-2020 | |
| Alkermes, INC. | $24.88 | 2022 | |
| Aytu Biopharma, INC. | $23.67 | 2020 | |
| Redhill Biopharma INC. | $22.96 | 2022 | |
| Mylan Specialty L.P. | $22.93 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.91 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.17 | 2020 | |
| Exact Sciences Corporation | $17.03 | 2025 | Cologuard Collection Kit |
| Dexcom, INC. | $14.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.95 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.49 | 2020 | |
| Eisai INC. | $13.03 | 2020 | |
| Scynexis, INC. | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francesca Cerimele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.